Ratio Analysis: Unpacking Gain Therapeutics Inc (GANX)’s Price-to-Cash and Price-to-Free Cash Flow

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $1.20 in the prior trading day, Gain Therapeutics Inc (NASDAQ: GANX) closed at $1.16, down -2.97%. In other words, the price has decreased by -$2.97 from its previous closing price. On the day, 0.16 million shares were traded. GANX stock price reached its highest trading level at $1.2 during the session, while it also had its lowest trading level at $1.13.

Ratios:

Our goal is to gain a better understanding of GANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on April 12, 2021, initiated with a Outperform rating and assigned the stock a target price of $30.

On April 12, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $30.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’24 when RICHMAN ERIC I bought 17,000 shares for $1.22 per share. The transaction valued at 20,670 led to the insider holds 289,629 shares of the business.

Riley Jeffrey Scott bought 30,000 shares of GANX for $115,770 on Mar 28 ’24. The Director now owns 30,000 shares after completing the transaction at $3.86 per share. On Dec 21 ’23, another insider, Alder Matthias, who serves as the Chief Executive Officer of the company, sold 206 shares for $2.46 each. As a result, the insider received 507 and left with 5,286 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 29195460 and an Enterprise Value of 8447333.

Stock Price History:

The Beta on a monthly basis for GANX is 0.35, which has changed by -0.7387388 over the last 52 weeks, in comparison to a change of 0.25510752 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $5.33, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -49.41%, while the 200-Day Moving Average is calculated to be -63.23%.

Shares Statistics:

The stock has traded on average 238.78K shares per day over the past 3-months and 397270 shares per day over the last 10 days, according to various share statistics. A total of 18.05M shares are outstanding, with a floating share count of 16.83M. Insiders hold about 6.75% of the company’s shares, while institutions hold 10.35% stake in the company. Shares short for GANX as of 1718323200 were 500330 with a Short Ratio of 2.10, compared to 1715731200 on 100709. Therefore, it implies a Short% of Shares Outstanding of 500330 and a Short% of Float of 2.97.

Most Popular